Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul 17;124(3):363-73.
doi: 10.1182/blood-2014-01-514786. Epub 2014 Jun 9.

Acute graft-versus-host disease: a bench-to-bedside update

Shernan G Holtan  1 , Marcelo Pasquini  2 , Daniel J Weisdorf  1
Affiliations
Review

Acute graft-versus-host disease: a bench-to-bedside update

Shernan G Holtan et al. Blood. .

Abstract

Over the past 5 years, many novel approaches to early diagnosis, prevention, and treatment of acute graft-versus-host disease (aGVHD) have been translated from the bench to the bedside. In this review, we highlight recent discoveries in the context of current aGVHD care. The most significant innovations that have already reached the clinic are prophylaxis strategies based upon a refinement of our understanding of key sensors, effectors, suppressors of the immune alloreactive response, and the resultant tissue damage from the aGVHD inflammatory cascade. In the near future, aGVHD prevention and treatment will likely involve multiple modalities, including small molecules regulating immunologic checkpoints, enhancement of suppressor cytokines and cellular subsets, modulation of the microbiota, graft manipulation, and other donor-based prophylaxis strategies. Despite long-term efforts, major challenges in treatment of established aGVHD still remain. Resolution of inflammation and facilitation of rapid immune reconstitution in those with only a limited response to corticosteroids is a research arena that remains rife with opportunity and urgent clinical need.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Initiation phase of aGVHD.
Figure 2
Figure 2
Expansion, trafficking, and effector phase of aGVHD.
Figure 3
Figure 3
Treatment phase of aGVHD.
See this image and copyright information in PMC

References

    1. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443–458. - PMC - PubMed
    1. Paczesny S, Hanauer D, Sun Y, Reddy P. New perspectives on the biology of acute GVHD. Bone Marrow Transplant. 2010;45(1):1–11. - PMC - PubMed
    1. Petersdorf EW. The major histocompatibility complex: a model for understanding graft-versus-host disease. Blood. 2013;122(11):1863–1872. - PMC - PubMed
    1. Kawase T, Morishima Y, Matsuo K, et al. Japan Marrow Donor Program. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood. 2007;110(7):2235–2241. - PubMed
    1. Kanda Y, Kanda J, Atsuta Y, et al. HLA working group of the Japan Society for Hematopoietic Cell Transplantation. Changes in the clinical impact of high-risk human leukocyte antigen allele mismatch combinations on the outcome of unrelated bone marrow transplantation. Biol Blood Marrow Transplant. 2014;20(4):526-535. - PubMed

Publication types

MeSH terms

Substances